Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2020 1
2021 19
2022 48
2023 55
2024 73
2025 62

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean texas treatment (238,791 results)?
VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP, Hinojosa-Azaola A, Sánchez-Hernández BE, Crispín JC, Apodaca-Chávez E, Ferrada MA, Martín-Nares E. Loeza-Uribe MP, et al. Reumatol Clin (Engl Ed). 2024 Jan;20(1):47-56. doi: 10.1016/j.reumae.2023.12.004. Epub 2023 Dec 29. Reumatol Clin (Engl Ed). 2024. PMID: 38160120 Free article. Review.
Patients with VEXAS syndrome exhibit inflammatory and hematological manifestations that can lead to clinical diagnoses such as relapsing polychondritis, polyarteritis nodosa, Sweet syndrome, and myelodysplastic syndrome. ...The aim of this review is to provide an ov …
Patients with VEXAS syndrome exhibit inflammatory and hematological manifestations that can lead to clinical diagnoses such as …
VEXAS syndrome: Current clinical, diagnostic and treatment approaches.
Kobak S. Kobak S. Intractable Rare Dis Res. 2023 Aug;12(3):170-179. doi: 10.5582/irdr.2023.01020. Intractable Rare Dis Res. 2023. PMID: 37662628 Free PMC article. Review.
Due to the recent discovery of VEXAS syndrome, ongoing research is being conducted to better understand its pathogenesis, clinical features, and potential treatment options. In this review article, the clinical, diagnostic and treatment approaches of …
Due to the recent discovery of VEXAS syndrome, ongoing research is being conducted to better understand its pathogenesis, clin …
VEXAS syndrome.
Grayson PC, Patel BA, Young NS. Grayson PC, et al. Blood. 2021 Jul 1;137(26):3591-3594. doi: 10.1182/blood.2021011455. Blood. 2021. PMID: 33971000 Free PMC article. Review.
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a monogenic disease of adulthood caused by somatic mutations in UBA1 in hematopoietic progenitor cells. ...VEXAS syndrome represents a prototype for a new class of diseases... …
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a monogenic disease of adulthood caused by somati …
Treatment Options for VEXAS Syndrome: Rapid Review.
Authors; Goring S, Horton J. Authors, et al. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov. PMID: 38620405 Free Books & Documents. Review. No abstract available.
An update on VEXAS syndrome.
Al-Hakim A, Savic S. Al-Hakim A, et al. Expert Rev Clin Immunol. 2023 Feb;19(2):203-215. doi: 10.1080/1744666X.2023.2157262. Epub 2022 Dec 26. Expert Rev Clin Immunol. 2023. PMID: 36537591 Free article. Review.
Current treatment and management options are discussed. EXPERT OPINION: New rare variants in UBA1 and VEXAS-like UBA1 negative cases are reported. ...Prospective studies are needed to define the optimal supportive and treatment options for patients with varyi …
Current treatment and management options are discussed. EXPERT OPINION: New rare variants in UBA1 and VEXAS-like UBA1 negative …
How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies.
Boyadzhieva Z, Ruffer N, Kötter I, Krusche M. Boyadzhieva Z, et al. Rheumatology (Oxford). 2023 Nov 2;62(11):3518-3525. doi: 10.1093/rheumatology/kead240. Rheumatology (Oxford). 2023. PMID: 37233149
OBJECTIVES: To evaluate the effectiveness and safety of current treatment strategies for the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. ...Three databases were searched for reports on treatment strategies for VEXAS …
OBJECTIVES: To evaluate the effectiveness and safety of current treatment strategies for the vacuoles, E1 enzyme, X-linked, autoinfla …
VEXAS Syndrome-Review.
Zhang Y, Dong X, Wang H. Zhang Y, et al. Glob Med Genet. 2023 Jul 10;10(3):133-143. doi: 10.1055/s-0043-1770958. eCollection 2023 Sep. Glob Med Genet. 2023. PMID: 37501758 Free PMC article. Review.
To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been established. Given the high mortality rate, VEXAS syndrome needs to be taken seriously by physicians in all specialties. This …
To date, patients respond poorly to immune suppressive drugs, except high-dose glucocorticoids, and no treatment guidelines have been …
JAK inhibitors for the treatment of VEXAS syndrome.
Bindoli S, Baggio C, Doria A, Bertoldo E, Sfriso P. Bindoli S, et al. Exp Biol Med (Maywood). 2023 May;248(5):394-398. doi: 10.1177/15353702231165030. Epub 2023 May 26. Exp Biol Med (Maywood). 2023. PMID: 37243340 Free PMC article. Review.
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a novel described autoinflammatory entity for which the diagnosis is defined by somatic mutations of the UBA1 X-linked gene in hematopoietic progenitor cells. ...However, recently described …
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a novel described autoinflammatory entity for whi …
VEXAS syndrome.
Nakajima H, Kunimoto H. Nakajima H, et al. Int J Hematol. 2024 May 31. doi: 10.1007/s12185-024-03799-9. Online ahead of print. Int J Hematol. 2024. PMID: 38819628 Review.
VEXAS syndrome is a recently identified, adult-onset autoinflammatory disease caused by somatic mutations in UBA1. ...Treatment of VEXAS syndrome is challenging and no consistently effective therapies have been established. ...
VEXAS syndrome is a recently identified, adult-onset autoinflammatory disease caused by somatic mutations in UBA1. ...Treat …
Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis.
Kilic B, Sacin E, Tanin MK, Kilinc OC, Ugurlu S. Kilic B, et al. Ann Hematol. 2025 May;104(5):2617-2630. doi: 10.1007/s00277-025-06382-2. Epub 2025 Apr 27. Ann Hematol. 2025. PMID: 40287866 Free PMC article. Review.
MEDLINE and EMBASE were screened from inception until March 2025. We included patients with VEXAS syndrome who received treatment with azacitidine, JAK inhibitors, IL-6 inhibitors, anti-IL-1, or anti-TNF agents. ...A total of 16 studies and 367 patients with …
MEDLINE and EMBASE were screened from inception until March 2025. We included patients with VEXAS syndrome who received tre …
228 results